Sunday , August 14 2022

Alzheimer's: cancellation results – 02/02/2019 – News



[ad_1]

Seven months after the total drugs were described in the treatment of Alzheimer's disease and associated diseases, the Alzheimer's Society of France and associated disease related diseases ran between October 9 and 16 November, 2018 in 2,547 people, including 2,463 carers and 84 sick people .
The society draws three direct results of these payments.

The first anxiety disorders associated with the disease: because 52% of respondents, quickening up the treatment suddenly result in the aggravation of these disorders.

The second discovery relates to the residual residue: 2 in 3 respondents took at least one drug at the time of publishing the inconsistency. If 70% of them do not intend to stop treatment (62.5% due to its effectiveness and 20% because their doctor advises it), 20% do not take it any more and 10% think stop it soon because of the cost high. The VAT on these drugs has increased by 2 to 10%.

The final result for patients is to break the therapeutic connection with the doctor: only 55% of people have decided not to take more treatments that will continue to consult with a specialist doctor, while 38% had already given the best visit and 7% considered it.

Finally, the survey shows that 68% of care donors and 77% of sick people believe that research must be one of government priorities. "In the face of government silence", France Alzheimer's and associated diseases have decided to finance a clinical study of € 200,000, which will study the impact of Donpezil's daily dose for patients' cognitive abilities for 3 years. The aim of this project is to provide new concrete results that can lead to the decision to repay these drugs ", explains the society.

[ad_2]
Source link